DNA and RNA Sequencing Recapitulated Aberrant Tumor Metabolism in Liver Cancer Cell Lines

Overview

Journal J Hepatocell Carcinoma

Date 2021 Aug 5

PMID 34350138

Authors

Yihong Sun

Xia Tang

Bo Ye

Keyue Ding

Affiliations

Soon will be listed here.

Abstract

Aim: Metabolic reprogramming has recently attracted extensive attention for understanding cancer development. We aimed to demonstrate a genomic and transcriptomic landscape of metabolic reprogramming underlying liver cancer cell lines.

Methods: We investigated metabolic aberrant at both the transcriptome and genome levels using transcriptome and whole-exome sequencing data from 12 human liver cancer cell lines (hLCCLs) and one normal liver cell line.

Results: Three subgroups of hLCCLs characterized from transcriptome sequencing data exhibit significantly different aberrations in various metabolic processes, including amino acid, lipid, energy, and carbohydrate metabolism. Furthermore, whole-exome sequencing revealed distinct mutational signatures among different subgroups of hLCCLs and identified a total of 19 known driver genes implicated in metabolism.

Conclusion: Our findings highlighted differential metabolic mechanisms in the development of liver cancer and provided a resource for further investigating its metabolic mechanisms.

References

Satoh S, Daigo Y, Furukawa Y, Kato T, Miwa N, Nishiwaki T . AXIN1 mutations in hepatocellular carcinomas, and growth suppression in cancer cells by virus-mediated transfer of AXIN1. Nat Genet. 2000; 24(3):245-50. DOI: 10.1038/73448. View

. Comprehensive and Integrative Genomic Characterization of Hepatocellular Carcinoma. Cell. 2017; 169(7):1327-1341.e23. PMC: 5680778. DOI: 10.1016/j.cell.2017.05.046. View

Yang W, Zhang X, Liu Y . Asialoglycoprotein receptor-targeted radiopharmaceuticals for measurement of liver function. Curr Med Chem. 2013; 21(1):4-23. DOI: 10.2174/09298673113209990213. View

De Matteis S, Ragusa A, Marisi G, De Domenico S, Casadei Gardini A, Bonafe M . Aberrant Metabolism in Hepatocellular Carcinoma Provides Diagnostic and Therapeutic Opportunities. Oxid Med Cell Longev. 2018; 2018:7512159. PMC: 6247426. DOI: 10.1155/2018/7512159. View

Anjanappa M, Hao Y, Simpson E, Bhat-Nakshatri P, Nelson J, Tersey S . A system for detecting high impact-low frequency mutations in primary tumors and metastases. Oncogene. 2017; 37(2):185-196. PMC: 5764779. DOI: 10.1038/onc.2017.322. View

Pannerec A, Migliavacca E, De Castro A, Michaud J, Karaz S, Goulet L . Vitamin B12 deficiency and impaired expression of amnionless during aging. J Cachexia Sarcopenia Muscle. 2017; 9(1):41-52. PMC: 5803611. DOI: 10.1002/jcsm.12260. View

Tong W, Rouault T . Distinct iron-sulfur cluster assembly complexes exist in the cytosol and mitochondria of human cells. EMBO J. 2000; 19(21):5692-700. PMC: 305809. DOI: 10.1093/emboj/19.21.5692. View

Bray F, Ferlay J, Soerjomataram I, Siegel R, Torre L, Jemal A . Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018; 68(6):394-424. DOI: 10.3322/caac.21492. View

Guzman-Lepe J, Cervantes-Alvarez E, Collin de lHortet A, Wang Y, Mars W, Oda Y . Liver-enriched transcription factor expression relates to chronic hepatic failure in humans. Hepatol Commun. 2018; 2(5):582-594. PMC: 5944584. DOI: 10.1002/hep4.1172. View

10.

Benzarti M, Delbrouck C, Neises L, Kiweler N, Meiser J . Metabolic Potential of Cancer Cells in Context of the Metastatic Cascade. Cells. 2020; 9(9). PMC: 7563895. DOI: 10.3390/cells9092035. View

11.

Tate J, Bamford S, Jubb H, Sondka Z, Beare D, Bindal N . COSMIC: the Catalogue Of Somatic Mutations In Cancer. Nucleic Acids Res. 2018; 47(D1):D941-D947. PMC: 6323903. DOI: 10.1093/nar/gky1015. View

12.

Barretina J, Caponigro G, Stransky N, Venkatesan K, Margolin A, Kim S . The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature. 2012; 483(7391):603-7. PMC: 3320027. DOI: 10.1038/nature11003. View

13.

Visvader J . Cells of origin in cancer. Nature. 2011; 469(7330):314-22. DOI: 10.1038/nature09781. View

14.

Lee S, Zhang C, Liu Z, Klevstig M, Mukhopadhyay B, Bergentall M . Network analyses identify liver-specific targets for treating liver diseases. Mol Syst Biol. 2017; 13(8):938. PMC: 5572395. DOI: 10.15252/msb.20177703. View

15.

Bailey M, Tokheim C, Porta-Pardo E, Sengupta S, Bertrand D, Weerasinghe A . Comprehensive Characterization of Cancer Driver Genes and Mutations. Cell. 2018; 173(2):371-385.e18. PMC: 6029450. DOI: 10.1016/j.cell.2018.02.060. View

16.

Nik-Zainal S, Alexandrov L, Wedge D, Van Loo P, Greenman C, Raine K . Mutational processes molding the genomes of 21 breast cancers. Cell. 2012; 149(5):979-93. PMC: 3414841. DOI: 10.1016/j.cell.2012.04.024. View

17.

Bergers G, Fendt S . The metabolism of cancer cells during metastasis. Nat Rev Cancer. 2021; 21(3):162-180. PMC: 8733955. DOI: 10.1038/s41568-020-00320-2. View

18.

Caruso S, Calatayud A, Pilet J, La Bella T, Rekik S, Imbeaud S . Analysis of Liver Cancer Cell Lines Identifies Agents With Likely Efficacy Against Hepatocellular Carcinoma and Markers of Response. Gastroenterology. 2019; 157(3):760-776. DOI: 10.1053/j.gastro.2019.05.001. View

19.

Love M, Huber W, Anders S . Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 2014; 15(12):550. PMC: 4302049. DOI: 10.1186/s13059-014-0550-8. View

20.

Liberzon A, Subramanian A, Pinchback R, Thorvaldsdottir H, Tamayo P, Mesirov J . Molecular signatures database (MSigDB) 3.0. Bioinformatics. 2011; 27(12):1739-40. PMC: 3106198. DOI: 10.1093/bioinformatics/btr260. View